Home > Research > Publications & Outputs > Refractory pruritus from malignant cholestasis

Electronic data

  • Refractory_pruritus_from_malignant_cholestasis

    Rights statement: This article has been accepted for publication in BMJ Supportive & Palliative Care, 2020 following peer review, and the Version of Record can be accessed online at http://dx.doi.org/10.1136/bmjspcare-2019-002051 © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) http://creativecommons.org BMJ Authors Self-Archiving Policy, September 2018 https://creativecommons.org/licenses/by-nc/4.0/

    Accepted author manuscript, 223 KB, PDF document

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Text available via DOI:

View graph of relations

Refractory pruritus from malignant cholestasis: Management

Research output: Contribution to journalJournal article

E-pub ahead of print
Article number002051
<mark>Journal publication date</mark>13/01/2020
<mark>Journal</mark>BMJ Supportive and Palliative Care
Number of pages3
Publication statusE-pub ahead of print
Early online date13/01/20
Original languageEnglish

Abstract

This case report deals with a patient managed in a tertiary-care cancer hospital who suffered pruritus associated with malignant cholestasis. His symptoms were resistant to conventional treatment with ursodeoxycholic acid, chlorpheniramine and cholestyramine. Hence, the multifactorial origin of malignancy-associated pruritus was considered. Correctable factors were corrected and generally the treatment was aimed at possible aetiologies. There were barriers related to insufficient resources available for symptom palliation in this particular setting, which could potentially reduce optimum symptom control. However, various pharmacotherapies and non-pharmacological measures which could potentially have helped relieve pruritus are described and future scope for research in this area discussed.

Bibliographic note

This article has been accepted for publication in BMJ Supportive & Palliative Care, 2020 following peer review, and the Version of Record can be accessed online at http://dx.doi.org/10.1136/bmjspcare-2019-002051 © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) http://creativecommons.org BMJ Authors Self-Archiving Policy, September 2018 https://creativecommons.org/licenses/by-nc/4.0/